LABORATORIOS FARMACEUTICOS ROVI, S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 84.3 EUR | +1.93% |
|
+6.10% | +40.03% |
| Apr. 02 | Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment | MT |
| Mar. 12 | Rovi, Partners to Form Entity for Advanced Therapies R&D | MT |
Evolution of the average Target Price on Laboratorios Farmaceuticos Rovi, S.A.
Price target over the last 5 years
History of analyst recommendation changes
977a7037795db804de8fa9b6d781c347.P1MI0ADp-NgALZ-iH7CyrAkN7Fmh3XWi0uPXmV5D3JU.TwNan3izvbpxZc-WbIjT-3NCmzj2rRrGpZua4zUJtv5lZjuhaNubuUxO8A~4a5d65996432bd642d7619551f570287
Analysts' Consensus
Sell
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
84.3
EUR
Average target price
85.12
EUR
Spread / Average Target
+0.98%
High Price Target
100
EUR
Spread / Highest target
+18.62%
Low Price Target
66
EUR
Spread / Lowest Target
-21.71%
Consensus detail
Consensus revision (last 18 months)
Trading Rating
Investor Rating
ESG Refinitiv
B+
EPS Revisions
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ROVI Stock
- Consensus Laboratorios Farmaceuticos Rovi, S.A.
